GENMAB A/S - AMERICAN DEPOSITARY SHARES
GENMAB A/S - AMERICAN DEPOSITARY SHARES
Certificado de depósito · US3723032062 · GMAB · A1WZYB (XNAS)
Resumen
22,21 USD
3,09 % 0,66 USD
NASDAQ (XNAS) · Precios actuales y gráficos en MoneyPeak
06.06.2025 19:59

Cotizaciones actuales de GENMAB A/S - AMERICAN DEPOSITARY SHARES

BolsaTickerMonedaÚltima operaciónPrecioVariación diaria
XNAS: NASDAQ
NASDAQ
GMAB
USD
06.06.2025 19:59
22,21 USD
21,81 USD
+1,81 %

Rendimiento

Día Semana Mes 3 meses 6 meses 1 año 5 años
0,00 % 5,94 % 8,74 % -6,35 % 1,81 % -22,22 % -23,64 %

Perfil de la empresa para GENMAB A/S - AMERICAN DEPOSITARY SHARES Certificado de depósito

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Fondos invertidos

Los siguientes fondos han invertido en: GENMAB A/S - AMERICAN DEPOSITARY SHARES invertido:

Fondo
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. en millones
77,21
Porcentaje (%)
0,18 %

Datos de la empresa

Nombre GENMAB A/S - AMERICAN DEPOSITARY SHARES
Empresa Genmab A/S
Símbolo GMAB
Sitio web https://www.genmab.com
Mercado principal XNAS NASDAQ
WKN A1WZYB
ISIN US3723032062
Tipo de valor Certificado de depósito
Sector Healthcare
Industria Biotechnology
CEO Dr. Jan G.J. van de Winkel Ph.D.
Capitalización de mercado 13 Mrd.
País Dinamarca
Moneda USD
Empleados 2,7 T
Dirección Kalvebod Brygge 43, 1560 Copenhagen
Fecha de OPV 2009-06-01

Splits de acciones

Fecha Split
01.05.2018 5:1

Cambios de identificador

Fecha De A
22.07.2019 GMXAY GMAB

Símbolos de cotización

Nombre Símbolo
Frankfurt GE91.F
NASDAQ GMAB

Otras acciones

Los inversores que tienen GENMAB A/S - AMERICAN DEPOSITARY SHARES también tienen las siguientes acciones en su cartera:
CABALETTA BIO INC
CABALETTA BIO INC Acción
TALLGRASS EN.P. 16/24
TALLGRASS EN.P. 16/24 Bono
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras. Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Aviso legal Protección de datos Blog Comunidad Comentarios Changelog
Im App Store herunterladen Bei Google Play herunterladen
Todos los derechos reservados © LCP GmbH 2025